Experienced in Peripheral Neuropathy

Hongyu Kuang

Harbin, CN 
Experienced in Peripheral Neuropathy
Harbin, CN 
OverviewLocationsClinical Research

Overview

Hongyu Kuang practices in Harbin, China. Mr. Kuang is rated as an Experienced expert by MediFind in the treatment of Peripheral Neuropathy. His top areas of expertise are Diabetic Retinopathy, Type 2 Diabetes (T2D), Peripheral Neuropathy, and Nonalcoholic Steatohepatitis (NASH).

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Peripheral Neuropathy.

Gender
Male

Locations

Harbin, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drugs: Dulaglutide, Insulin Glargine
Study Phase: Phase 3
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

46 Total Publications

Semaglutide ameliorates retinal vascular permeability destruction in diabetic retinopathy by AnxA2-mediated MMP-9 activation and basement membrane remodeling.
Semaglutide ameliorates retinal vascular permeability destruction in diabetic retinopathy by AnxA2-mediated MMP-9 activation and basement membrane remodeling.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kuang's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile